

消化器外科学講座

【研究プロジェクト名および概要】

I. 消化管領域における研究

- ・ 食道癌手術後の呼吸器合併症減少を目指した革新的リスク評価法の確立
- ・ 胃 CMS 2/3 大腸癌に対する代謝関連蛋白阻害剤を用いた新規治療法の開発
- ・ 大腸癌に対する革新的治療戦略構築を目指した患者体組成に関する網羅的解析
- ・ 胃癌腹膜播種における腫瘍不均一性及び腫瘍微小環境を標的とした革新的治療法の開発
- ・ 遺伝性胃癌臨床検体の NGS 解析による新たな分子生物学的発癌メカニズムの解明
- ・ 大腸癌に対するがん免疫療法における革新的治療予測バイオマーカーの探索
- ・ 大腸癌の抗腫瘍免疫におけるニュートリエピジェネティクス
- ・ *Fusobacterium* が癌関連線維芽細胞と関連して消化器癌へ及ぼす影響のメカニズム解明
- ・ 革新的治療法開発を目指したサルコペニアと腫瘍免疫の統合的解析
- ・ *F. nucleatum* による大腸癌進展と鉄の関連

II. 肝・胆膵領域における研究

- ・ 肝癌における C5aR と PD-L1 阻害剤との相互作用を介した革新的治療の開発
- ・ MYC と PGC1 α が制御する癌代謝と腫瘍免疫を標的とした新規肝細胞癌治療法の開発
- ・ 新規免疫治療標的やバイオマーカー同定のための胃癌腹膜播種の動的免疫微小環境の解析
- ・ 糖・アミノ酸代謝シフトによる膵がん代謝制御機構の解明
- ・ がん - ストロマー代謝物クロストークによる膵癌進展メカニズムの解明
- ・ リキッドバイオプシーを用いた膵癌個別化治療のための腹膜播種予測 miRNA パネルの開発
- ・ アルコール性肝炎によるミトコンドリア PGAM5 を軸とした肝障害のメカニズム解明

III. 外科一般に関する研究

- ・ 消化器癌の発達・進展に關与する癌関連遺伝子の網羅的解析とバイオマーカー探索
- ・ 消化器癌における腸内細菌叢の解明
- ・ 消化器癌におけるレトロトランスポズンの解明
- ・ 癌代謝が消化器癌に及ぼす生理学的意義の解明
- ・ 消化器癌における癌関連線維芽細胞の機能解明と制御、癌との相互作用に関する研究

【教職員・医員および大学院生】

准教授 宮本 裕士
特任准教授 馬場 祥史
特任准教授 岩槻 政晃
講師 林 洋光
診療講師 井田 智
診療講師 岡部 弘尚
診療講師 日吉 幸晴
特任助教 中川 茂樹
特任助教 江藤 弘二郎
特任助教 小澄 敬祐
助教 大内 繭子
特任助教 北野 雄希
助教 伊東山 瑠美
救急助教 小川 克大
特任助教 問端 輔
医員 原 淑大、高田 一登、安部 禎人、松本 将弥、大村 亮太、東 陽子、高津 研翔、鈴木 裕紀子、式地 優樹、高橋 啓太、島本 将希

大学院生 (4 年生) 小川 大輔、前田 裕斗、光浦 智証、湯本 信成、武 曦昱
大学院生 (3 年生) 足立 優樹、金光 紘介、田尻 拓哉、堀野 大智、佟 依霖、王 懷涛、王 浩林
大学院生 (2 年生) 耕 佳徹、谷崎 卓実、張 衛麗雲、董 翰宸、韓 錦濤、孫 宇軒
大学院生 (1 年生) 椿原 拓樹、中村 尋、酒匂 照生、久野 祐樹
研究生 丁 銘、吳 霄漢、宋 銘洋

【メールアドレス】

miyamotoyuji@kumamoto-u.ac.jp
y-baba@kumamoto-u.ac.jp
maiwa217@kumamoto-u.ac.jp
hhayasi@kumamoto-u.ac.jp
sdaidaida@yahoo.co.jp
hirohisaokabe1251@yahoo.co.jp
yukiharu0606@yahoo.co.jp
shigekn2@gmail.com
etouetouetou@yahoo.co.jp
peugeolf_ksk_0930@yahoo.co.jp
mayuko030964@kumamoto-u.ac.jp
beat11100411@yahoo.co.jp
itoyama_rumi@yahoo.co.jp
kogawa@kumamoto-u.ac.jp
t1293t@yahoo.co.jp

【研究プロジェクト】

I, II, III (研究の統括)
I, III
I, III
II, III
I, III
II, III
I, III
I, III
I, III
II, III
II, III
I, III
I, III
II, III
I, III
I, III

【連絡先】 電話: 096-373-5212 Fax: 096-371-4378

【ホームページ】 <http://kumamoto-gesurg.com/>

【特殊技術・装置】

臨床：食道・胃・大腸癌に対する完全鏡視下手術、腹腔鏡下 肝・膵切除、ダヴィンチ Si

特許：膵臓切離断端固定クリップ (特願 2019-050488)

基礎：DNA メチル化/遺伝子発現/代謝解析、遺伝子 Knock down/Overexpression、ゲノム編集 (CRISPR-Cas9 system)、切除検体由来癌関連線維芽細胞樹立、イメージング (BZ-X 蛍光顕微鏡, IncuCyte)、マウスモデル(移植：同所/異所, allogenic/syngenic, 発がん)、FlowCytometry/CyToF を用いた single cell 解析および sorting、三次元培養システム

【英文論文】

1. Uemura N, Hayashi H, Liu Z, Matsumura K, Ogata Y, Yasuda N, Sato H, Shiraishi Y, Miyata T, Nakagawa S, Mima K, Nitta H, Baba H: Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 expression in pancreatic cancer. *Am J Cancer Res* 13:2041-2054, 2023
2. Iwatsuki M, Matsumoto C, Mimori K, Baba H: The comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment. *Ann Gastroenterol Surg* 7:725-732, 2023
3. Kobayashi H, Kotake K, Kawasaki M, Kanemitsu Y, Kinugasa Y, Ueno H, Maeda K, Suto T, Itabashi M, Funahashi K, Ozawa H, Koyama F, Noura S, Ishida H, Ohue M, Kiyomatsu T, Ishihara S, Koda K, Baba H, Kawada K, Hashiguchi Y, Goi T, Toiyama Y, Tomita N, Sunami E, Akagi Y, Watanabe J, Hakamada K, Nakayama G, Sugihara K, Ajioka Y: A proposed new Japanese classification of synchronous peritoneal metastases from colorectal cancer: A multi-institutional, prospective, observational study conducted by the Japanese Society for Cancer of the Colon and Rectum. *Ann Gastroenterol Surg* 7:765-771, 2023
4. Mima K, Nakagawa S, Miyata T, Yamashita YI, Baba H: Frailty and surgical outcomes in gastrointestinal cancer: Integration of geriatric assessment and prehabilitation into surgical practice for vulnerable patients. *Ann Gastroenterol Surg* 7:27-41, 2023
5. Miyamoto Y, Ogawa K, Ohuchi M, Tokunaga R, Baba H: Emerging evidence of immunotherapy for colorectal cancer. *Ann Gastroenterol Surg* 7:216-224, 2023
6. Nakamura I, Hatano E, Baba H, Kamei K, Wada H, Shimizu J, Kanai M, Yoshimura K, Nagano H, Ioka T: Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. *Ann Gastroenterol Surg* 7:1009-1020, 2023
7. Ichida A, Kokudo T, Shimada S, Hatano E, Kubo S, Kato Y, Ishikawa Y, Mori A, Baba H, Matsuyama Y, Endo I, Yamaue H, Yamamoto M, Kokudo N, Hasegawa K: Liver resection for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium: A large-scale multicenter survey conducted in Japan. *Ann Surg* 278:e549-e555, 2023
8. Zhao Y, Peng F, Wang C, Murano T, Baba H, Ikematsu H, Li W, Goel A: A DNA methylation-based epigenetic signature for the identification of lymph node metastasis in T1 colorectal cancer. *Ann Surg* 277:655-663, 2023
9. Harada K, Matsumoto C, Toihata T, Kosumi K, Iwatsuki M, Baba Y, Ohuchi M, Eto K, Ogawa K, Sawayama H, Iwagami S, Miyamoto Y, Yoshida N, Baba H: C-reactive protein levels after esophagectomy are associated with increased surgical complications and poor prognosis in esophageal squamous cell carcinoma patients. *Ann Surg Oncol* 30:1554-1563, 2023
10. Ikenaga N, Miyasaka Y, Ohtsuka T, Nakata K, Adachi T, Eguchi S, Nishihara K, Inomata M, Kurahara H, Hisaka T, Baba H, Nagano H, Ueki T, Noshiro H, Tokunaga S, Ishigami K, Nakamura M, Kyushu Study Group of treatment for pancreatobiliary C: A prospective multicenter phase II trial of neoadjuvant chemotherapy with Gemcitabine plus Nab-Paclitaxel for borderline resectable pancreatic cancer with arterial involvement. *Ann Surg Oncol* 30:193-202, 2023
11. Kitano Y, Inoue Y, Takeda T, Oba A, Ono Y, Sato T, Ito H, Ozaka M, Sasaki T, Sasahira N, Baba H, Takahashi Y: Clinical efficacy of neoadjuvant chemotherapy with Gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma compared with upfront surgery. *Ann Surg Oncol* 30:5093-5102, 2023
12. Morinaga T, Iwatsuki M, Yamashita K, Yasuda-Yoshihara N, Yamane T, Matsumoto C, Harada K, Eto K, Kurashige J, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H: Dynamic alteration in HLA-E expression and soluble HLA-E via interaction with natural killer cells in gastric cancer. *Ann Surg Oncol* 30:1240-1252, 2023
13. Morito A, Harada K, Iwatsuki M, Maeda Y, Mitsuura C, Toihata T, Kosumi K, Eto K, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Baba H: Frailty Assessed by the Clinical Frailty Scale is Associated with Prognosis After Esophagectomy. *Ann Surg Oncol* 30:3725-3732, 2023
14. Arima K, Uemura N, Tsuneyoshi K, Fujita H, Kuroki H, Uemura S, Hanada N, Baba H, Komohara Y: Microsatellite instability-high signet ring cell carcinoma of the colon treated with immunotherapy: Report of a Case. *Anticancer Res* 43:4729-4733, 2023
15. Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D, Inoue M, Mizumoto T, Kubota T, Yanagida E, Murayama T, Miyanari N, Baba H: Conversion surgery after Atezolizumab plus Bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. *Anticancer Res* 43:943-947, 2023
16. Tomita M, Okabe H, Masuda T, Ono A, Kuroda D, Kuroki H, Hirota M, Hibi T, Baba H, Sugita H: A case of accessory hepatic duct entering cystic duct successfully treated by laparoscopic cholecystectomy for cholecystolithiasis. *Asian J Endosc Surg* 16:546-549, 2023
17. Tubakihara H, Sawayama H, Komohara Y, Miyamoto Y, Ogawa K, Ohuchi M, Yoshida N, Baba H: A case of familial adenomatous polyposis with protein-losing enteropathy treated by laparoscopic total colorectal resection: A literature review. *Asian J Endosc Surg* 16:77-81, 2023
18. Stachler MD, Bao C, Tourdot RW, Brunette GJ, Stewart C, Sun L, Baba H, Watanabe M, Agoston A, Jajoo K, Davison JM, Nason K, Getz G, Wang KK, Imamura Y, Odze R, Bass AJ, Zhang C-Z: Origins of cancer genome complexity revealed by haplotype-resolved genomic analysis of evolution of Barrett's esophagus to esophageal adenocarcinoma. *bioRxiv:2021.2003.2026.437288*, 2023
19. Kosumi K, Baba Y, Yamamura K, Nomoto D, Okadome K, Yagi T, Toihata T, Kiyozumi Y, Harada K, Eto K, Sawayama H, Ishimoto T, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Watanabe M, Baba H: Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer. *Br J Cancer* 128:1155-1165, 2023
20. Liu Z, Hayashi H, Matsumura K, Ogata Y, Sato H, Shiraishi Y, Uemura N, Miyata T, Higashi T, Nakagawa S, Mima K, Imai K, Baba H: Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer. *Br J Cancer* 128:844-856, 2023
21. Saito Y, Fujiwara Y, Miyamoto Y, Ohnishi K, Nakashima Y, Tabata Y, Baba H, Komohara Y: CD169(+) sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. *Cancer Med* 12:10199-10211, 2023
22. Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BKY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, Wei F, Fu L, Zhang J, Kitamura F, Yamashita K, Eto K, Iwagami S, Tsukamoto H, Umemoto T, Masuda M, Nagano O, Satou Y, Saya H, Tan P, Baba H, Ishimoto T: Stromal reprogramming through dual PDGFRalpha/beta blockade boosts the efficacy of anti-PD-1 immunotherapy in fibrotic tumors. *Cancer Res* 83:753-770, 2023
23. Liu Z, Hayashi H, Matsumura K, Uemura N, Shiraishi Y, Sato H, Baba H: Biological and clinical impacts of glucose metabolism in pancreatic ductal adenocarcinoma. *Cancers* 15:498, 2023
24. Miyamoto Y, Akiyama T, Kato R, Sawayama H, Ogawa K, Yoshida N, Baba H: Prognostic significance of systemic inflammation indices by K-ras status in patients with metastatic colorectal cancer. *Dis Colon Rectum* 66:e809-e817,

2023

25. Baba Y, Hara Y, Toihata T, Kosumi K, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Baba H: Relationship between gut microbiome *Fusobacterium nucleatum* and LINE-1 methylation level in esophageal cancer. *Esophagus* 20:704-712, 2023
26. Yoshida N, Eto K, Horinouchi T, Shiraishi S, Kanemitsu K, Ofuchi T, Tajiri T, Adachi Y, Horino T, Morito A, Mitsuura C, Maeda Y, Hara Y, Matsumoto C, Baba H: Prognostic value of (18)F-fluorodeoxyglucose uptake in the bone marrow on pretreatment positron emission tomography/computed tomography in patients with esophageal cancer who underwent esophagectomy. *Esophagus* 20:660-668, 2023
27. Shiraishi K, Nakaura T, Uetani H, Nagayama Y, Kidoh M, Kobayashi N, Morita K, Yamahita Y, Tanaka Y, Baba H, Hirai T: Deep learning-based reconstruction and 3D hybrid profile order technique for MRCP at 3T: evaluation of image quality and acquisition time. *Eur Radiol* 33:7585-7594, 2023
28. Wei F, Uchihara T, Yonemura A, Yasuda-Yoshihara N, Yasuda T, Semba T, Fukuda M, Akiyama T, Kitamura F, Bu L, Hu X, Fu L, Zhang J, Kariya R, Yamasaki J, Aihara K, Yamashita K, Nagano O, Okada S, Baba H, Ishimoto T: A novel tdTomato transgenic mouse model to visualize FAP-positive cancer-associated fibroblasts. *FEBS J* 290:2604-2615, 2023
29. Yasuda T, Baba H, Ishimoto T: Cellular senescence in the tumor microenvironment and context-specific cancer treatment strategies. *FEBS J* 290:1290-1302, 2023
30. Zhang J, Fu L, Yasuda-Yoshihara N, Yonemura A, Wei F, Bu L, Hu X, Akiyama T, Kitamura F, Yasuda T, Semba T, Uchihara T, Itoyama R, Yamashita K, Eto K, Iwagami S, Yashiro M, Komohara Y, Baba H, Ishimoto T: IL-1beta derived from mixed-polarized macrophages activates fibroblasts and synergistically forms a cancer-promoting microenvironment. *Gastric Cancer* 26:187-202, 2023
31. Fujiwara N, Kubota N, Zhu S, Nakagawa S, Baba H, Hoshida Y: Disseminative recurrence signature for hepatocellular carcinoma from nonalcoholic fatty liver disease. *Gastro hep advances* 2:681-683, 2023
32. Maeda Y, Eto K, Yoshida N, Iwatsuki M, Iwagami S, Ogawa K, Sawayama H, Baba Y, Miyamoto Y, Baba H: The 5-factor modified frailty index is a novel predictive marker of death from other diseases after curative gastrectomy for gastric cancer. *Geriatr Gerontol Int* 23:750-756, 2023
33. Mima K, Hayashi H, Yumoto S, Matsumoto T, Tsukamoto M, Miyata T, Nakagawa S, Nitta H, Baba H: Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma. *Hepato Res* 53:135-144, 2023
34. Kawata A, Miyamoto Y, Fukubayashi K, Horio T, Miyamoto H, Ogawa K, Ouchi M, Tanaka Y, Baba H: Conversion surgery after Encorafenib plus Cetuximab for chemorefractory BRAF V600E-mutated colorectal cancer with para-aortic lymph node metastases. *In Vivo* 37:1797-1801, 2023
35. Hirao H, Okabe H, Masuda T, Ogawa D, Uemura N, Kuroda D, Taki K, Tomiyasu S, Hirota M, Hibi T, Baba H, Sugita H: Intestinal fluid CT level could predict pathological small bowel ischemia in small bowel obstruction. *Indian J Surg* 85:596-601, 2023
36. Omachi K, Imai K, Nakao Y, Nakamura H, Kaida T, Shiraishi Y, Itoyama R, Nitta H, Hayashi H, Asato T, Mikami Y, Baba H: A surgical resection of hepatic granuloma mimicking intrahepatic cholangiocarcinoma: a case report. *Int Cancer Conf J* 12:195-199, 2023
37. Horino T, Tokunaga R, Miyamoto Y, Hiyoshi Y, Akiyama T, Daitoku N, Sakamoto Y, Yoshida N, Baba H: The impact of the advanced lung cancer inflammation index on the outcomes of patients with metastatic colorectal cancer who receive chemotherapy. *Int J Clin Oncol* 28:400-408, 2023
38. Kato R, Miyamoto Y, Ouchi M, Ogawa K, Yoshida N, Baba H: The Geriatric Nutritional Risk Index is a prognostic marker in patients with metastatic colorectal cancer. *Int J Clin Oncol* 28:893-900, 2023
39. Kayashima H, Itoh S, Shimokawa M, Hayashi H, Takamori H, Fukuzawa K, Ninomiya M, Araki K, Yamashita YI, Sugimachi K, Uchiyama H, Morine Y, Utsunomiya T, Uwagawa T, Maeda T, Baba H, Yoshizumi T: Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial. *Int J Clin Oncol* 28:1520-1529, 2023
40. Maehara Y, Oki E, Ota M, Harimoto N, Ando K, Nakanishi R, Kawazoe T, Fujimoto Y, Nonaka K, Kitao H, Iimori M, Makino K, Takechi T, Sagara T, Miyadera K, Matsuoka K, Tsukihara H, Kataoka Y, Wakasa T, Ochiwa H, Kamahori Y, Tokunaga E, Saeki H, Yoshizumi T, Kakeji Y, Shirabe K, Baba H, Shimada M: Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii. *Int J Clin Oncol* 28:613-624, 2023
41. Okui J, Shigeta K, Kato Y, Mizuno S, Sugiura K, Seo Y, Nakada J, Baba H, Kikuchi H, Hirata A, Makino A, Kondo T, Matsui S, Seishima R, Okabayashi K, Obara H, Sato Y, Kitagawa Y: Delayed-onset organ/space surgical site infection worsens prognosis in high-risk stage II and III colorectal cancer. *J Gastrointest Surg* 27:2515-2525, 2023
42. Kanaka S, Matsuda A, Yamada T, Miyamoto Y, Yokoyama Y, Matsumoto S, Sonoda H, Ohta R, Shinji S, Sekiguchi K, Baba H, Yoshida H: Segmental or right hemi-colectomy? The optimal surgical procedure for transverse colon cancer: a propensity score-matched, multicenter, retrospective study. *Int J Colorectal Dis* 38:58, 2023
43. Yoshida N, Eto K, Matsumoto T, Kosumi K, Imamura Y, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Baba H: Omental flap wrapping around the esophagogastric anastomosis and association with anastomotic leak in esophagectomy for esophageal cancer: A propensity score-matching analysis. *J Am Coll Surg* 236:189-197, 2023
44. Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H, Kansai Hepatobiliary Oncology G: Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). *J Hepatobiliary Pancreat Sci* 30:102-110, 2023
45. Akiyama T, Miyamoto Y, Matsuda A, Tokunaga R, Ogawa K, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Sonoda H, Yamada T, Yoshida H, Baba H: The colon inflammatory index score can predict the survival outcome after resection of colorectal cancer: a retrospective multicenter study. *J Cancer Res Clin Oncol* 149:7887-7894, 2023
46. Hu X, Yasuda T, Yasuda-Yoshihara N, Yonemura A, Umemoto T, Nakachi Y, Yamashita K, Semba T, Arima K, Uchihara T, Nishimura A, Bu L, Fu L, Wei F, Zhang J, Tong Y, Wang H, Iwamoto K, Fukuda T, Nakagawa H, Taniguchi K, Miyamoto Y, Baba H, Ishimoto T: Downregulation of 15-PGDH enhances MASH-HCC development via fatty acid-induced T-cell exhaustion. *JHEP reports : innovation in hepatology* 5:100892, 2023
47. Ijima H, Fukuda Y, Uehara MK, Shafiq M, Wu FQ, Cho JY, Sakai Y, Miyata T, Yamao T, Nakao Y, Kuroda Y, Motomura T, Yamashita YI, Baba H: Decellularized mouse liver as a small-scale scaffold for the creation of a miniaturized human liver. *J Chem Eng Jpn* 56:1, 2023
48. Mima K, Baba H: Outcomes of patients with frailty and metastatic cancer admitted to the intensive care unit. *Lancet Healthy Longev* 4:e655-e656, 2023
49. Imai K, Baba H: Initially unresectable colorectal liver metastases: the best therapeutic regimens. *Lancet Oncol* 24:711-

50. Maeda Y, Iwatsuki M, Mitsuura C, Morito A, Ohuchi M, Kosumi K, Eto K, Ogawa K, Baba Y, Iwagami S, Miyamoto Y, Yoshida N, Baba H: Textbook outcome contributes to long-term prognosis in elderly colorectal cancer patients. *Langenbecks Arch Surg* 408:245, 2023
51. Morito A, Iwatsuki M, Maeda Y, Mitsuura C, Hara Y, Matsumoto C, Toihata T, Kosumi K, Eto K, Baba Y, Iwagami S, Miyamoto Y, Yoshida N, Baba H: Textbook outcome contributes to long-term prognosis in older adults with gastric cancer. *Langenbecks Arch Surg* 408:324, 2023
52. Ogawa K, Shiraishi Y, Karashima R, Nitta H, Masuda T, Matsumoto K, Sawayama H, Miyamoto Y, Baba H, Takamori H: Prolonged door-to-antibiotics time is associated with high hospital mortality in patients with perforated colorectal peritonitis. *Langenbecks Arch Surg* 408:220, 2023
53. Bao C, Tourdot RW, Brunette GJ, Stewart C, Sun L, Baba H, Watanabe M, Agoston AT, Jajoo K, Davison JM, Nason KS, Getz G, Wang KK, Imamura Y, Odze R, Bass AJ, Stachler MD, Zhang CZ: Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma. *Nat Commun* 14:6203, 2023
54. Shindo Y, Nagano H, Kanai M, Kobayashi S, Wada H, Sakai D, Eguchi H, Baba H, Kamachi H, Takayama T, Ueno M, Takahashi M, Nakagami Y, Yoshimura K, Hatano E, Ioka T: Clinical outcomes of second-line chemotherapy after gemcitabine and cisplatin plus S-1 treatment for patients with advanced biliary tract cancer in the KHBO1401-3A study. *Oncol Rep* 49:41, 2023
55. Kobayashi S, Wada H, Sakai D, Baba H, Kanai M, Kamachi H, Takayama T, Ueno M, Takahashi M, Sho M, Yoshimura K, Hatano E, Nagano H, Ioka T: Impact of tumor shrinkage pattern with biweekly triplet gemcitabine+cisplatin+S-1 regimen for biliary tract cancers: Implications for neoadjuvant therapy from the data of KHBO1401 (KHBO1401-1A study). *Oncology*:1-10, 2023
56. Lan C, Yamashita YI, Tsukamoto M, Hayashi H, Nakagawa S, Liu Z, Wu X, Imai K, Mima K, Kaida T, Baba H: The prognostic role of serine racemase in patients with pancreatic cancer: A new marker in cancer metabolism. *Pancreas* 52:e101-e109, 2023
57. Horino T, Miyamoto Y, Ohuchi M, Ogawa K, Yoshida N, Ishiko T, Kakinaka C, Sasaki R, Ohba T, Baba H: Repeated intestinal perforations in vascular Ehlers-Danlos syndrome: a case report of a novel mutation in the COL3A1 gene. *Surg Case Rep* 9:78, 2023
58. Kitamura F, Semba T, Yasuda-Yoshihara N, Yamada K, Nishimura A, Yamasaki J, Nagano O, Yasuda T, Yonemura A, Tong Y, Wang H, Akiyama T, Matsumura K, Uemura N, Itoyama R, Bu L, Fu L, Hu X, Wei F, Mima K, Imai K, Hayashi H, Yamashita YI, Miyamoto Y, Baba H, Ishimoto T: Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. *JCI Insight* 8:e163022, 2023
59. Lou M, Iwatsuki M, Wu X, Zhang W, Matsumoto C, Baba H: ASO Author Reflections: The significance of IL-8 expression in cancer-associated fibroblast of gastric cancer. *Ann Surg Oncol*, 2023 Dec 12. doi: 10.1245/s10434-023-14660-4. Online ahead of print.
60. Lou M, Iwatsuki M, Wu X, Zhang W, Matsumoto C, Baba H: Cancer-associated fibroblast-derived IL-8 upregulates PD-L1 expression in gastric cancer through the NF-kappaB pathway. *Ann Surg Oncol*, 2023 Nov 25. doi: 10.1245/s10434-023-14586-x. Online ahead of print.
61. Morito A, Eto K, Iwatsuki M, Toihata T, Kosumi K, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Baba H: Clinical impact of very early recurrence after conversion surgery for stage IV gastric cancer. *Ann Gastroenterol Surg*, Sep 14. doi: org/10.1002/ags3.12738. Online ahead of print.
62. Wu X, Iwatsuki M, Takaki M, Saito T, Hayashi T, Kondo M, Sakai Y, Gotohda N, Tanaka E, Nishida T, Baba H: FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1. *Gastric Cancer*, 2023 Dec 24. doi: 10.1007/s10120-023-01454-6. Online ahead of print.
63. Takematsu T, Mima K, Hayashi H, Kitano Y, Nakagawa S, Hiyoshi Y, Okabe H, Imai K, Miyamoto Y, Baba H: RAS mutation status in combination with the JSHBPS nomogram may be useful for preoperative identification of colorectal liver metastases with high risk of recurrence and mortality after hepatectomy. *J Hepatobiliary Pancreat Sci*, 2023 Oct 27. doi: 10.1002/jhbp.1389. Online ahead of print.
64. Kato M, Sawayama H, Komohara Y, Hisano Y, Nakamura H, Ohuchi M, Ogawa K, Miyamoto Y, Yoshida N, Baba H: Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report. *Clin J Gastroenterol* 17:57-64, 2024
65. Kitano Y, Ono Y, Kobayashi K, Oba A, Sato T, Ito H, Inoue Y, Shinozaki E, Yamaguchi K, Saiura A, Baba H, Takahashi Y: Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study. *HPB (Oxford)* 26:282-290, 2024
66. Mima K, Hayashi H, Maruno M, Yumoto S, Matsumoto T, Tsukamoto M, Miyata T, Nakagawa S, Nitta H, Imai K, Baba H: Perioperative disabilities in activities of daily living are associated with worse prognosis after hepatectomy for colorectal liver metastasis. *HPB (Oxford)* 26:203-211, 2024
67. Horino T, Tokunaga R, Miyamoto Y, Akiyama T, Daitoku N, Sakamoto Y, Ohuchi M, Ogawa K, Yoshida N, Baba H: Extracellular water to total body water ratio, a novel predictor of recurrence in patients with colorectal cancer. *Ann Gastroenterol Surg* 8:98-106, 2024
68. Li L, Kanemitsu K, Ohnishi K, Yamada R, Yano H, Fujiwara Y, Miyamoto Y, Mikami Y, Hibi T, Baba H, Komohara Y: CXCL10 expression in human colorectal cancer tissue and its correlation with serum levels of CXCL10. *Cancer Genomics Proteomics* 21:54-64, 2024
69. Baba Y, Yasuda N, Bundo M, Nakachi Y, Ueda J, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Oshiumi H, Iwamoto K, Baba H: LINE-1 hypomethylation, increased retrotransposition and tumor-specific insertion in upper gastrointestinal cancer. *Cancer Sci* 115:247-256, 2024
70. Yonemura A, Semba T, Zhang J, Fan Y, Yasuda-Yoshihara N, Wang H, Uchihara T, Yasuda T, Nishimura A, Fu L, Hu X, Wei F, Kitamura F, Akiyama T, Yamashita K, Eto K, Iwagami S, Iwatsuki M, Miyamoto Y, Matsusaki K, Yamasaki J, Nagano O, Saya H, Song S, Tan P, Baba H, Ajani JA, Ishimoto T: Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. *Cell Rep* 43:113613, 2024
71. Mima K, Hayashi H, Adachi Y, Tajiri T, Ofuchi T, Kanemitsu K, Ogawa D, Yumoto S, Matsumoto T, Itoyama R, Kitano Y, Nakagawa S, Okabe H, Baba H: Patient vulnerability is associated with poor prognosis following upfront hepatectomy for colorectal liver metastasis. *Int J Clin Oncol* 29:47-54, 2024
72. Ogawa D, Miyata T, Yumoto S, Shiraishi Y, Matsumoto T, Takematsu T, Tsukamoto M, Nakagawa S, Mima K, Nitta H, Hayashi H, Baba H: Prognostic value of preoperative geriatric nutritional risk index in intrahepatic cholangiocarcinoma after hepatectomy: a single-center retrospective cohort study. *Langenbecks Arch Surg* 409:47, 2024
73. Horinouchi T, Yoshida N, Shiraishi S, Hara Y, Matsumoto C, Toihata T, Kosumi K, Harada K, Eto K, Ogawa K,

Sawayama H, Iwatsuki M, Baba Y, Miyamoto Y, Baba H: Relationship between the severity of emphysematous change in the lung and morbidity after esophagectomy for esophageal cancer: A retrospective study on a novel strategy for risk prediction. *Thorac Cancer* 15:15-22, 2024

74. Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, Tateishi R, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen P, Moriwaki H, Suzuki H: Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. *Int J Cancer*, in press.